E.g., 05/12/2021
E.g., 05/12/2021

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

As the incidence of infections with the SARS-CoV-2 Omicron variant (B.1.1. 529) continues to rise, there is much concern about diagnostic tests ability to efficiently detect this multi-mutated form of the COVID-19 virus.

01 December, 2021

Since the beginning of the pandemic bioMérieux's research and development teams have closely monitored the emergence of each variants of concern and systematically conducted in-depth in silico internal analyses.

These analyses allow us to confirm that to date our BIOFIRE...

bioMérieux – Third-Quarter 2021 Business Review

Marcy l’Étoile, October 21, 2021 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2021.

21 October, 2021

  • Organic growth of 12.1% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €2,452 million in sales
    • Up 8.2% as reported
  • Q3 sales organic growth at 11.6%, significantly...

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

DEERFIELD, Ill., AND MARCY L’ETOILE, FRANCE, OCTOBER 21, 2021 – Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEARCCL14 Test. The NEPHROCLEAR CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR CCL14 Test in western Europe in 2022.

21 October, 2021

“Baxter is proud to partner with bioMérieux to offer the NEPHROCLEAR CCL14 Test as an important new diagnostic option to support individualized AKI management that gives every patient the greatest opportunity for recovery,” said Reaz Rasul, general manager of...

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

Marcy l’Étoile, France and London, UK – September 13th, 2021 –  On World Sepsis Day, bioMérieux, a world leader in the field of in vitro diagnostics, and the UK Sepsis Trust, an internationally renowned charity committed to help put an end to preventable deaths from sepsis and improve outcome for its survivors, reveal the results of a survey conducted in Europe* regarding knowledge and attitudes towards sepsis. The findings demonstrate the need to accelerate awareness and education of the general population about this life-threatening condition.

13 September, 2021

Sepsis is a life-threatening organ dysfunction caused by an excessive immune response to a serious infection. Every year worldwide 49 million people develop  sepsis, of whom 11 million do not survive.

bioMérieux has long been committed to the fight against sepsis and is working...

bioMérieux – First-Half 2021 Results

01 September, 2021

  • €1,574 million in first-half 2021 sales, up 12.3% like-for-like
  • Q2 sales organic growth at 7.9% in line with our expectations: slowdown in molecular biology, strong growth of immunoassays, and good momentum in microbiology and industrial applications...

In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

Marcy l’Étoile, France and Mountain View, California – bioMérieux, a world leader in the field of in vitro diagnostics, and Specific Diagnostics, a company bringing unique in vitro diagnostic systems to clinical microbiology, announce that bioMérieux will distribute Specific Diagnostics’ newly introduced REVEAL Rapid AST system in Europe.

29 June, 2021

In the context of the global threat from Antimicrobial Resistance (AMR), clinicians need to receive faster antibiotic susceptibility test (AST) results and accurate interpretation, to enable timely and optimized patient intervention. In bloodstream infections, an urgent and often life-...

bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants

bioMérieux, a world leader in the field of in vitro diagnostics, has launched EPISEQ® SARS-COV-2, a genomic software solution to support microbiology labs in identification and reporting from raw sequencing data related to SARS-CoV-2 variants.

24 June, 2021

Viral mutation is a naturally occurring phenomenon leading to the emergence of variants that can have different characteristics. Today, a number of SARS-CoV-2 variants are circulating worldwide. Some of these variants are under particular scrutiny because of their impact on the pandemic (...

bioMérieux announces the CE marking of the new generation semi-quantitative VIDAS® SARS-COV-2 IgG II serology test.  

bioMérieux, a world leader in the field of in vitro diagnostics, today announces CE marking of the new generation of IgG serology test with VIDAS® SARS-COV-2 IgG II to semi-quantitatively detect antibodies in people who have been exposed to the SARS-CoV-2 that causes the COVID-19 disease.

07 May, 2021

In 2021, on top of the importance of detecting COVID-19 virus, the emergence of variant strains and expansion of vaccination have generated new public health challenges. In particular, obtaining quantitative serological information by measuring antibody levels might provide important insights to...

bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the CE-marking of VITEK® MS PRIME, the next generation of the VITEK® MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes.

30 April, 2021

Rapid microorganism identification is a pivotal step in the microbiology workflow. Over the past decade, MALDI-TOF mass spectrometry has transformed this process, providing critical information rapidly to clinicians in order to prescribe more effective antimicrobial therapy.


bioMérieux – First-Quarter 2021 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2021.

27 April, 2021

  • First-quarter organic growth of 16.5% at constant exchange rates and scope of consolidation : €845 million in sales, up 9.9% as reported.
  • Molecular biology up 19% over the quarter, with a slowdown in BIOFIRE® respiratory panels’ demand...